Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.

Authors:
Ilaria J Chicca Jennifer L J Heaney Gulnaz Iqbal Janet A Dunn Stella Bowcock Guy Pratt Kwee L Yong Timothy D Planche Alex Richter Mark T Drayson

Blood Cancer J 2020 11 4;10(11):114. Epub 2020 Nov 4.

Institute of Immunology and Immunotherapy, Clinical Immunology Service, University of Birmingham, Birmingham, UK.

Multiple myeloma (MM) is associated with increased risk of infection, but little is known regarding antibody levels against specific bacteria. We assessed levels of polyclonal immunoglobulin and antibacterial antibodies in patients recruited to the TEAMM trial, a randomised trial of antibiotic prophylaxis at the start of anti-myeloma treatment. Polyclonal IgG, IgA and IgM levels were below the reference range in 71%, 83% and 90% of 838 MM patients at diagnosis. Anti-vaccine targeted tetanus toxoid antibodies were protective in 95% of 193 healthy controls but only 41% of myeloma patients. In healthy controls, protective antibodies against 6/12 pneumococcal serotypes, haemophilus and meningococcus A were present in 67%, 41% and 56% compared to just 15%, 21% and 17% of myeloma patients. By 1 year, myeloma patients IgG levels had recovered for 57% of patients whilst the proportion with protective levels of IgG against thymus-dependent protein antigen tetanus toxoid had changed little. In contrast the proportions of patients with protective levels against thymus independent polysaccharide antigens pneumococcus, haemophilus and meningococcus had fallen from 15 to 7%, 21 to 0% and 17 to 11%. Findings highlight the need for strategies to protect patients against bacterial infections during therapy and vaccination programmes during remission.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-00370-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642409PMC
November 2020

Publication Analysis

Top Keywords

myeloma patients
16
patients
9
tetanus toxoid
8
haemophilus meningococcus
8
protective levels
8
healthy controls
8
multiple myeloma
8
levels
6
myeloma
5
range 71%
4
meningococcus 67%
4
serotypes haemophilus
4
6/12 pneumococcal
4
antibodies 6/12
4
67% 41%
4
pneumococcal serotypes
4
reference range
4
15% 21%
4
21% 17%
4
17% myeloma
4

Keyword Occurance

Similar Publications

Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma.

Authors:
Aimee M Merino Rohtesh S Mehta Xianghua Luo Hansol Kim Todd De For Murali Janakiram Sarah Cooley Rose Wangen Frank Cichocki Daniel J Weisdorf Jeffrey S Miller Veronika Bachanova

Transplant Cell Ther 2021 Apr 17;27(4):310.e1-310.e6. Epub 2020 Dec 17.

Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Adaptive natural killer (NK) cells are long-lived and exhibit properties of immunologic memory against cytomegalovirus (CMV). We previously reported that expansion of adaptive NK cells after CMV reactivation in recipients of allogeneic hematopoietic cell transplantation (HCT) was associated with a lower rate of relapse of acute myelogenous leukemia. In the present study, we examined the impact of adaptive NK cell expansion in a cohort of 110 individuals who underwent autologous HCT (AHCT) for a lymphoid malignancy (lymphoma or multiple myeloma [MM]). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.

Authors:
Harsh Parmar Abdullah S Al Saleh Alissa Visram Rahma Warsame Taxiarchis Kourelis Wilson Gonsalves David Dingli Eli Muchtar Suzanne Hayman Prashant Kapoor Francis Buadi Angela Dispenzieri Martha Lacy Morie Gertz Shaji Kumar

Transplant Cell Ther 2021 Apr 17;27(4):309.e1-309.e5. Epub 2020 Dec 17.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address:

Patients who undergo autologous stem cell transplantation (ASCT) for multiple myeloma (MM) are routinely assessed at day +100 using serum and urine protein electrophoresis/immunofixation and the serum free light chain (sFLC) assay. We evaluated whether an increase in M-spike or FLC from immediately before ASCT to day +100 post-ASCT has any prognostic impact. We retrospectively reviewed 1218 patients with MM at the Mayo Clinic who underwent their first ASCT between 2000 and 2016. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a analysis of phase 3 clinical trials.

Authors:
Jiasheng Wang Changsu Park Raul Arroyo-Suarez

Leuk Lymphoma 2021 Apr 9:1-8. Epub 2021 Apr 9.

Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.

It is unknown if daratumumab could affect venous thromboembolism (VTE) risks in patients with multiple myeloma (MM). In this study, individual participant data from three trials comparing daratumumab (DARA) and non-DARA regimens, the CASTOR, PULLOX and MAIA trial, were pooled into two groups. A total of 896 and 899 patients received DARA and non-DARA regimens, respectively. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Disruptive technologies for hemodialysis: medium and high cutoff membranes. Is the future now?

Authors:
Thiago Reis Siddiq Anwar Francisco de Assis da Rocha Neves Claudio Ronco

J Bras Nefrol 2021 Apr 9. Epub 2021 Apr 9.

San Bortolo Hospital, International Renal Research Institute of Vicenza, Department of Nephrology, Dialysis and Transplantation, Vicenza, Italy.

In the past decade, a new class of hemodialysis (HD) membranes (high retention onset class) became available for clinical use. The high cutoff (HCO) and the medium cutoff (MCO) membranes have wider pores and more uniformity in pore size, allowing an increased clearance of uremic toxins. Owing to the mechanism of backfiltration/internal filtration, middle molecules are dragged by the convective forces, and no substitution solution is needed. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma.

Authors:
Rodrigo Carlini Fernando Fabrício de Carvalho Adriana Franco Paes Leme Gisele Wally Braga Colleoni

Front Oncol 2021 23;11:563384. Epub 2021 Mar 23.

Department of Experimental and Clinical Oncology, Discipline of Hematology and Hemotherapy, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.

Although the "seed and soil" hypothesis was proposed by Stephen Paget at the end of the 19th century, where he postulated that tumor cells (seeds) need a propitious medium (soil) to be able to establish metastases, only recently the tumor microenvironment started to be more studied in the field of Oncology. Multiple myeloma (MM), a malignancy of plasma cells, can be considered one of the types of cancers where there is more evidence in the literature of the central role that the bone marrow (BM) microenvironment plays, contributing to proliferation, survival, migration, and drug resistance of tumor cells. Despite all advances in the therapeutic arsenal for MM treatment in the last years, the disease remains incurable. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap